Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Harvard Business School
Cipla
Julphar
AstraZeneca
McKinsey
Moodys
US Department of Justice
QuintilesIMS

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SYMMETREL

« Back to Dashboard

Clinical Trials for Symmetrel

Trial ID Title Status Sponsor Phase Summary
NCT00627250 Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability Completed U.S. Department of Education N/A The purpose of this study is to determine if amantadine hydrochloride given 100 mg in the morning and at noon is safe and effective in the treatment of mood and behavior changes (i.e. irritability) after sustaining traumatic brain injury.
NCT00627250 Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability Completed Carolinas Healthcare System N/A The purpose of this study is to determine if amantadine hydrochloride given 100 mg in the morning and at noon is safe and effective in the treatment of mood and behavior changes (i.e. irritability) after sustaining traumatic brain injury.
NCT00867139 TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients Completed Fred Hutchinson Cancer Research Center Phase 1/Phase 2 The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
NCT00975611 Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation Terminated Ortho-McNeil Janssen Scientific Affairs, LLC Phase 4 The purpose of this study is to show that amantadine might help to reduce the side effect of the medications which are prescribed to treat schizophrenia or schizoaffective disorder. High level of hormone prolactin, or hyperprolactinemia, is one of the side effects which might be developed in patients treated with the paliperidone ER or risperidone Consta. High level of prolactin might stimulate breast development, might decrease sexual desire (libido). The goals of this study are to demonstrate that amantadine lowers prolactin levels, decreases side effects, and improves psychiatric symptoms.
NCT00975611 Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation Terminated David C. Henderson, MD Phase 4 The purpose of this study is to show that amantadine might help to reduce the side effect of the medications which are prescribed to treat schizophrenia or schizoaffective disorder. High level of hormone prolactin, or hyperprolactinemia, is one of the side effects which might be developed in patients treated with the paliperidone ER or risperidone Consta. High level of prolactin might stimulate breast development, might decrease sexual desire (libido). The goals of this study are to demonstrate that amantadine lowers prolactin levels, decreases side effects, and improves psychiatric symptoms.
NCT01071395 Validation of Dyskinesia Rating Scales Completed Michael J. Fox Foundation for Parkinson's Research Phase 4 This study will evaluate the responsiveness of a variety of available dyskinesia rating scales to treatment with amantadine or placebo in Parkinson's disease patients with dyskinesia. The study will be a parallel, double-blind, randomized trial of 68 patients treated with amantadine or placebo for 8 weeks. Pre-treatment evaluations will be performed and compared to end of study evaluations on the best treatment dose (200 or 300 mg amantadine or matching placebo) daily. Safety evaluations will be conducted. The responsiveness of the different scales will be evaluated statistically with a mixed model in which changes in the outcome measures over time will include a fixed effect of treatment group assignment. The model will additionally account for random effects of intercepts (the scale scores at baseline) that will include both random variation (person-specific) and specific variation associated with rate of change in outcome. The investigators may include adjustments for possible confounding covariates, including baseline demographics and center. The goal of the program is to provide researchers with the best scale(s) to distinguish dyskinesia change in Parkinson's disease (PD) associated with amantadine in comparison to placebo and to establish the magnitude of effect achievable with amantadine as a comparator "gold standard" that must be met or surpassed by future anti-dyskinetic agents. Additionally, with the use of paper and pencil questionnaires, the study will investigate the impact of patient optimism and patient and rater expectation of positive effects on the dyskinesia rating outcomes.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Symmetrel

Condition Name

Condition Name for Symmetrel
Intervention Trials
Traumatic Brain Injury 2
Parkinson's Disease 2
Influenza 1
Heart Arrest 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Symmetrel
Intervention Trials
Parkinson Disease 2
Brain Injuries 2
Heart Arrest 1
Aggression 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Symmetrel

Trials by Country

Trials by Country for Symmetrel
Location Trials
United States 10
Canada 1
France 1
Austria 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Symmetrel
Location Trials
Illinois 3
Florida 1
Alabama 1
Massachusetts 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Symmetrel

Clinical Trial Phase

Clinical Trial Phase for Symmetrel
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Symmetrel
Clinical Trial Phase Trials
Completed 3
Terminated 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Symmetrel

Sponsor Name

Sponsor Name for Symmetrel
Sponsor Trials
Northwestern University 1
U.S. Department of Education 1
Rush University Medical Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Symmetrel
Sponsor Trials
Other 8
U.S. Fed 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Cipla
Daiichi Sankyo
Moodys
Mallinckrodt
US Department of Justice
US Army
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.